Weekly Carfilzomib Quadruplet Has Promise in Newly Diagnosed Myeloma
C. Ola Landgren, MD, PhD, discusses data from the phase 2 MANHATTAN trial, which showed that carfilzomib (Kyprolis), lenalidomide (Revlimid), dexamethasone, and daratumumab (Darzalex) yielded high rates of minimal residual disease negativity in patients with newly diagnosed multiple myeloma.
Weekly Carfilzomib Quadruplet Induces High Rates of MRD Negativity, PFS in Newly Diagnosed Myeloma
The quadruplet combination comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab was linked with high rates of minimal residual disease negativity and progression-free survival in patients with newly diagnosed multiple myeloma.
Landgren Lauds Promise of Carfilzomib Quadruplet Regimen in Newly Diagnosed Myeloma
June 16th 2021C. Ola Landgren, MD, PhD, discusses important research efforts that led to the launch of the phase 2 MANHATTAN trial, the results achieved with the weekly carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, and the potential for this approach irrespective of transplant eligibility status.
Landgren Spotlights Safety Considerations for Carfilzomib Quadruplet in Newly Diagnosed Myeloma
June 17th 2021C. Ola Landgren, MD, PhD, discusses key safety considerations with a novel carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, the clinical implications of the phase 2 MANHATTAN trial, and next steps for this research.
